About: The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
Creator	Chen, Xi Gong, Zhicheng Liu, Wanli Qian, Long Shen, Qiuying Wang, Xiang Wei, Jie Xu, Zhijie Yan, Yuanliang Yang, Xue Zeng, Shuangshuang Bergandi, Loredana Maletzki, Claudia
Source	Medline; PMC
abstract	Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting cancer progression. Alone or in combination treatments, studies have shown that NM attenuates various malignant tumors, including pancreatic, colorectal, gastric, gallbladder, and hepatocellular cancers. In this review, based on several activating pathways, including the canonical Nuclear factor-κB (NF-κB) signaling pathway, tumor necrosis factor receptor-1 (TNFR1) signaling pathway, and tumorigenesis-related tryptase secreted by mast cells, we summarize the anticancer properties of NM in existing studies both in vitro and in vivo. In addition, the efficacy and side effects of NM in cancer patients are summarized in detail. To further clarify NM's antitumor activities, clinical trials devoted to validating the clinical applications and underlying mechanisms are needed in the future.
has issue date	2019-09-03(xsd:dateTime)
bibo:doi	10.3389/fonc.2019.00852
bibo:pmid	31552177
has license	cc-by
sha1sum (hex)	84b4e11342098e8595165eff814c004ec50d3e0e
schema:url	https://doi.org/10.3389/fonc.2019.00852
resource representing a document's title	The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
has PubMed Central identifier	PMC6733886
has PubMed identifier	31552177
schema:publication	Front Oncol
resource representing a document's body	covid:84b4e11342098e8595165eff814c004ec50d3e0e#body_text
is schema:about of	named entity 'anticancer' named entity 'gastric' named entity 'future' named entity 'attenuates' named entity 'Mesylate' named entity 'MOLECULAR' named entity 'NEEDED' named entity 'NAFAMOSTAT MESYLATE' named entity 'INCREASING' named entity 'TUMORIGENESIS' named entity 'CANCER PROGRESSION' named entity 'PATIENTS' named entity 'REVIEW' named entity 'VARIOUS' named entity 'TREAT' named entity 'PATHWAYS' named entity 'PANCREATITIS' named entity 'SYNTHETIC' named entity 'BASED' named entity 'EFFECTS' named entity 'PANCREATIC' named entity 'CLINICAL TRIALS' named entity 'STUDIES' named entity 'GALLBLADDER' named entity 'INCLUDING' named entity 'PROPERTIES' named entity 'COMBINATION' named entity 'TREATMENTS' named entity 'MAST CELLS' named entity 'SECRETED' named entity 'TUMOR NECROSIS FACTOR RECEPTOR' named entity 'PLACED' named entity 'SIDE EFFECTS' named entity 'APPROVED' named entity 'ANTITUMOR' named entity '27S' named entity 'FUTURE' named entity 'ACTIVATING' named entity 'EFFICACY' named entity 'NUCLEAR' named entity 'ADDITION' named entity 'PROTEASE INHIBITOR' named entity 'CLINICAL' named entity 'ITS' named entity 'EFFECTS' named entity 'ACTIVITIES' named entity 'INHIBITING' named entity 'APPLICATIONS' named entity 'COLORECTAL' named entity 'ANTITUMOR' named entity 'NAFAMOSTAT MESYLATE' named entity 'JAPAN' named entity 'POTENTIAL' named entity 'ASPECT' named entity 'APPLICATIONS' named entity 'IN VITRO' named entity 'CLINICAL' named entity 'TOBACCO' named entity 'DISEASES' named entity 'FACTOR' named entity 'CANCER' named entity 'UNDERLYING' named entity 'MARKET' named entity 'HAVE' named entity 'RECENTLY' named entity 'SERINE PROTEASE INHIBITOR' named entity 'MALIGNANT TUMORS' named entity 'ANTICANCER' named entity 'SIGNALING PATHWAY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software